| 1. Hardware | |||
|---|---|---|---|
| a. Field strength [T] | 3 T | 3 T | |
| b. Manufacturer | Siemens | Siemens | |
| c. Model (software version if available) | Skyra (VD13B) | Skyra (VD13B) | |
| d. RF coils: nuclei (transmit/receive), number of channels, type, body part | 32 ch 1H head coil | 32 ch 1H head coil | |
| e. Additional hardware | N/A | N/A |
| 2. Acquisition | |||
|---|---|---|---|
| a. Pulse sequence | PRESS | Semi‐LASER CSI | |
| b. Volume of interest (VOI) locations |
Patients: lesion Controls: centrum semiovale |
Patients: lesion | |
| c. Nominal VOI size [cm3, mm3] | 20 × 20 × 20 mm3 | 80 × 80 × 15 mm3 | |
| d. Repetition time (T R), echo time (T E) [ms, s] | T R = 2000 ms, T E = 97 ms | T R = 1700 ms, T E = 97 ms | |
|
e. Total number of excitations or acquisitions per spectrum In time series for kinetic studies i. Number of averaged spectra (NA) per time point ii. Averaging method (eg block‐wise or moving average) iii. Total number of spectra (acquired/in time series) |
128 averages | 3 averages | |
|
f. Additional sequence parameters (bandwidth in Hz or dwell time in ms, number of spectral points, frequency offsets) If STEAM: mixing time (T M) If MRSI: 2D or 3D, FOV in all directions, matrix size, acceleration factors, sampling method |
1200 Hz, 1024 points | 2D: 160 × 160 × 15 mm3 FOV; matrix size 16 × 16, no acceleration factor; weighted distribution sampling | |
| g. Water suppression method | WET | WET | |
| h. Shimming method, reference peak, and thresholds for “acceptance of shim” chosen | Automated 3D B 0 field mapping technique followed by manual adjustment <14 Hz | Automated 3D B 0 field mapping technique followed by manual adjustment <25 Hz | |
| i. Triggering or motion correction method (respiratory, peripheral, cardiac triggering, incl. device used and delays) | N/A | N/A |
| 3. Data analysis methods and outputs | |||
|---|---|---|---|
| a. Analysis software | LCmodel 6.2 | LCmodel 6.2 | |
| b. Processing steps deviating from quoted reference or product | Custom basis set | Custom basis set | |
| c. Output measure (eg absolute concentration, institutional units, ratio), processing steps deviating from quoted reference or product | Ratios to creatine | Ratios to creatine | |
| d. Quantification references and assumptions, fitting model assumptions | The basis set included spectra of 2HG, NAA, GABA, glutamate, glycine, creatine, myo‐inositol, glutamine, lactate, alanine, acetate, aspartate, ethanolamine, glutathione, phosphorylethanolamine, scyllo‐inositol, taurine, N‐acetylaspartylglutamate, glucose, and choline simulated using real pulses. Macromolecules were not modelled. | The basis set included spectra of 2HG, NAA, GABA, glutamate, glycine, creatine, myo‐inositol, glutamine, lactate, alanine, acetate, aspartate, ethanolamine, glutathione, phosphorylethanolamine, scyllo‐inositol, taurine, N‐acetylaspartylglutamate, glucose, and choline simulated using real pulses. Macromolecules were not modelled. | |
| 4. Data quality | |||
| a. Reported variables (SNR, linewidth (with reference peaks)) | SNR and linewidths not reported | SNR and linewidths not reported | |
| b. Data exclusion criteria | SNR < 5 or FWHM of creatine peak > 0.143 ppm | 75th percentile 2HG/creatine values of the selected voxels | |
| c. Quality measures of postprocessing model fitting (eg CRLB, goodness of fit, SD of residual) | 2HG CRLB < 30% | 2HG CRLB < 30% | |
| d. Sample spectrum | Figures 1‐3 | Figures 1‐3 | |
The example above used the following paper: Zhou M, Zhou Y, Liao H, et al. Diagnostic accuracy of 2‐hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomas. Neuro‐Oncol. 2018;20(9):1262‐1271. https://doi.org/10.1093/neuonc/noy022.
Items listed in italics are details that were not included in the paper that served as the source for this example.